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Abstract 
Current prediction models for risk of cardio-
vascular disease (CVD) incidence incorporate
smoking  as  a  dichotomous  yes/no  measure.
However,  the  risk  of  CVD  associated  with
smoking  also  varies  with  the  intensity  and
duration  of  smoking  and  there  is  a  strong
association between time since quitting and
the risk of disease onset. This study aims to
develop improved risk prediction equations for
CVD  incidence  incorporating  intensity  and
duration of smoking and time since quitting.
The risk of developing a first CVD event was
evaluated using a Cox’s model for participants
in  the  Framingham  offspring  cohort  who
attended  the  fourth  examination  (1988-92)
between the ages of 30 and 74 years and were
free of CVD (n=3751). The full models based
on the smoking variables and other risk fac-
tors, and reduced models based on the smok-
ing variables and non-laboratory risk factors
demonstrated good discrimination, calibration
and global fit. The incorporation of both time
since quitting among past smokers and pack-
years among current smokers resulted in bet-
ter predictive performance as compared to a
dichotomous  current/non-smoker  measure
and a current/quitter/never smoker measure.
Compared to never smokers, the risk of CVD
incidence  increased  with  pack-years.  Risk
among  those  quitting  more  than  five  years
prior  to  the  baseline  exam  and  within  five
years prior to the baseline exam were similar
and twice as high as that of never smokers.  A
CVD risk equation incorporating the effects of
pack-years and time since quitting provides an
improved tool to quantify risk and guide pre-
ventive care. 
Introduction
Cigarette smoking is an important risk fac-
tor  for  developing  cardiovascular  disease
(CVD).
1-4 The risk of CVD increases with the
number of cigarettes smoked and with dura-
tion  of  smoking  and  there  is  a  substantial
increase  in  CVD  mortality  for  continuing
smokers  compared  with  ex-smokers.
5 Also,
there  is  a  lag  between  smoking  behavior
among ex-smokers and disease onset, so that
past smoking behavior will influence health
status in current non-smokers.
6 For ex-smok-
ers,  increasing  intervals  since  quitting  are
associated  with  a  progressively  lower  CVD
mortality  rate,  risk  of  myocardial  infarction
and ischemic stroke until it levels off.
7-9
Smoking  acts  synergistically  with  other
major risk factors of CVD such as age, sex,
high  blood  pressure,  dyslipidemia  and  dia-
betes.
10 This has led to the development and
validation of a number of multivariable risk
models  which  can  be  used  by  primary  care
physicians  to  assess  the  risk  in  individual
patients  of  developing  all  atherosclerotic
CVD
11-20 or specific types of CVD, namely, coro-
nary  heart  disease,
10,20-25 stroke,
26 peripheral
vascular disease,
27 or heart failure.
28 Multiva  -
riable assessment has been advocated to esti-
mate absolute CVD risk and guide treatment
of  risk  factors,
2,29 and  the  Framingham  CVD
risk  assessment  tool  and  other  similar  risk
assessment tools have been validated
22,23,25 and
also re-calibrated in other ethnically diverse
populations.
10,17,20,26-29
This study seeks to examine the role of cig-
arette smoking as a risk factor in risk models
in greater detail than the simple dichotomous
yes/no variable
1-3 that has been incorporated in
all the existing risk prediction models. Risk
equations will be developed incorporating the
effect of pack-years, time since quitting, and
combined effects of intensity and duration of
smoking, the latter variables being more read-
ily  available  to  general  practitioners  (GPs)
than pack-years. This study will also develop
reduced  equations  based  on  the  detailed
smoking  measures  and  risk  factors  readily
available to GPs such as non-laboratory risk
factors. In this study, we use a slightly modi-
fied Framingham risk equation as the refer-
ence equation. Alcohol intake is included as it
is a possible confounder of cigarette smoking
with CVD risk, and systolic (SBP) and diastolic
(DBP) blood pressures are included since a
recent Framingham based risk model for CVD
risk
20 demonstrated improved predictive per-
formance  when  both  these  measures  were
included in the risk model.
Materials and Methods
The details for design, selection criteria,
examination  procedures  and  an  operative
definition  of  CVD  for  the  Framingham
Offspring  Heart  Study  have  been  provided
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elsewhere.
20,26-29 To provide current estimates
of CVD risk over a broad age range, smoking
status information from the first examination
was carried forward to the fourth examina-
tion (1988 to 1992). Participants were eligible
for the present study if they were free of CVD,
aged 30-74 with complete data on covariates.
Participants aged 75 years and older  were
excluded because of possible differences in
risk factors in this older group and its poten-
tially large influence in the algorithm deter-
mination. After exclusions, the sample con-
sisted of 3,751 participants (mean age 51.61
years; 1,937 women). 
Measurement of developing cardio-
vascular disease risk factors
The Framingham Offspring study collected
data on smoking status, the number of ciga-
rettes smoked per day, age at starting regular
smoking, and age at quitting smoking. The
risk  factors  included  in  the  models  were
smoking status (defined according to the par-
ticular study objective), both components of
blood pressure (SBP and DBP), either total
cholesterol/HDL ratio or both HDL and total
cholesterol depending on which provides bet-
ter prediction, age, sex, diabetes status, body
mass index (BMI) and alcohol consumption.
In the Framingham Offspring study, at each
examination participants underwent a physi-
cal examination, anthropometry, blood pres-
sure determination, and phlebotomy for vas-
cular  risk  factors.  The  examination  blood
pressure was calculated as the average of 2
physician-obtained  measures.  Standardized
enzymatic methods were used to determine
serum total and HDL cholesterol levels. The
various measures of cigarette smoking were
obtained by self-report. Diabetes was defined
as a fasting glucose of above 126 mg/dL. 
Examination 4 was considered the baseline
for our study as this had CVD data for a broad
age  range.  Information  on  time  since  quit-
ting, age at quitting and duration of smoking
were not available at this examination. First,
age at quitting at examination 4 was estimat-
ed  from  information  of  this  variable  from
examination  1  and  smoking  history  from
examinations 1 through to 4. For those who
were quitters at both examinations 1 and 4
but  resumed  smoking  in  between  the  two
examinations, their age at quitting at exami-
nation 1 was carried forward to examination
4 by adding their age at quitting at examina-
tion  1  to  the  time  interval  they  remained
smokers  after  examination  1.  Similarly,  for
those who were smokers at examination 1 but
quitters at examination 4, this was estimated
by taking the average of the age at quitting
and the preceding age. Time since quitting at
examination 4 was estimated by subtracting
age at quitting at examination 4 from current
age at examination 4. 
For those who were smokers at both exam-
inations 1 and 4, their duration of smoking at
examination 1 was carried forward to exami-
nation 4 by adding their duration of smoking
at  examination  1  to  the  interval  they
remained  smokers  after  examination  1.
Similarly, for those who were non-smokers at
examination 1 but smokers at examination 4,
this  was  estimated  as  the  interval  they
remained smokers after examination 1.   
Categories of smoking
Current pack-years of smoking were calcu-
lated  by  dividing  the  number  of  cigarettes
being smoked per day by 20 to obtain an esti-
mate of “packs” and multiplying this by the
number of years a person is a smoker. To sep-
arate the effect of past smoking and current
pack-years  of  smoking  and  assess  a  dose-
response pattern, the smoking status and cur-
rent  pack-years  were  combined  into  a  five-
category  “pack-years”  variable  defined  as:
never smokers, former smokers and current
smokers with under 20, 20-39, and 40 or more
pack-years.  Other  categorizations  for  pack-
years were found to be less effective in terms
of predictive ability. To separate the effect of
current  smoking  and  time  since  quitting
among  past  smokers  and  assess  a  dose-
response  pattern,  the  smoking  status  and
time  since  quitting  were  combined  into  a
four-category  variable  defined  as:  never
smokers, former smokers with five years or
less and over five years since quitting, and
current smokers. Compared to the cut-off of
five  years,  other  categorizations  for  time
since quitting did not predict the risk of CVD
incidence as well. To assess the joint effects
of intensity and duration of smoking, current
smokers were classified into 9 groups with
three levels of intensity (<20, 20-39 and 40+
pack-years) at each of three levels of duration
(<30, 30-39 and 40+ years).
Development and assessment of
predictive models
Three groups of models were fitted, each
incorporating the range of risk factors listed
above. The first group focused on the effect of
pack-years of smoking (among current smok-
ers). First a model with a simple binary cur-
rent/non-smoker measure for smoking status
was  compared  to  an  equivalent  model  with
the pack-years variable defined above. Then,
a  model  with  a  current/past/never  smoker
measure for smoking status was compared to
the model containing the pack-years variable.
A similar approach was adopted for a second
group of models focussed on time since quit-
ting, and for a third group including the joint
effects of intensity and duration of smoking
among current smokers in the smoking status
variable. While developing the risk equations,
only  those  risk  factors  which  were  signifi-
cantly related to the risk of CVD incidence
were included in the model. 
For each of the three groups of models, we
also fitted reduced models incorporating the
smoking  variables  and  non-laboratory  risk
factors.  The  non-laboratory  risk  factors
included age, sex, SBP, DBP, BMI and alcohol
consumption.  The  full  and  reduced  models
were  compared  to  examine  whether  use  of
only non-laboratory risk factors instead of all
the risk factors resulted in a significant loss
in prediction or not. In some of the risk equa-
tions,  the  ratio  of  total  cholesterol  to  HDL
cholesterol was used because no improved fit
was  found  when  the  covariates  were  used
separately. 
We used Cox’s proportional-hazards regres-
sions
30 to relate risk factors to the incidence
of a CVD event during a follow up from exam
4 to exam 7 after confirming that the assump-
tion of proportionality of hazards was met. For
testing proportionality of hazards a non-sig-
nificant interaction between a covariate and
log (survival time) would support the assump-
tion for the covariate.
31 This was complement-
ed  by  the  plotting  of  Schoenfeld  residuals
against survival time. 
The discriminative ability of a model was
assessed  by  Harrell’s  c  statistic.
32,33 Harrell
recommends  using  bootstrap  techniques  to
assess the degree of ‘overoptimism’ in the c
statistic due to using the same data for model
fitting and assessment. We applied this tech-
nique  and  found  negligible  overoptimism
with the bias in all the c-statistic estimates
less than 0.006. To assess the improvement in
discrimination  between  two  nested  models,
we used a test for difference in two correlated
c statistics.
34 But for models containing stan-
dard risk factors and possessing reasonably
good  discrimination,  very  large  “indepen-
dent” associations of the new covariate with
the outcome are required to provide a mean-
ingfully larger c statistic.
35-37 To overcome this
limitation of c statistic, the NRI
38 and IDI
38 pro-
vide  valuable  supplements  to  the  c-statistic
analyses.
38,39 These attempt to quantify in dif-
ferent ways  the level of shift in the distribu-
tion of absolute risk after a new covariate is
included in the model. For calculating NRI, we
assessed risk reclassification
38 by sorting the
predicted  risk  for  each  model  into  3  cate-
gories (<6%, 6% to <20%, and ≥20%). The
benefit and cost of using a new model com-
pared to the baseline model was measured by
the proportions of subjects with and without
subsequent events, respectively, who are clas-
sified as high-risk (e.g. ≥20%) according to
the model.
40 To assess calibration of the fitted
model, we computed the Hosmer-Lemeshow
statistic and its modification for the reclassi-
fication tables.
38 A significant value for this
statistic  indicates  poor  calibration.  We  alsoArticle
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performed  likelihood  ratio  tests  to  evaluate
whether the global model fit improved after
the inclusion of additional covariates. Finally,
we  assessed  the  overall  goodness  of  fit  for
each of the models using BIC and AIC. These
allow us to rank the models’ goodness of fit
adjusting for model parsimony.
Results
The risk factor characteristics in our sam-
ple at the baseline examination 4 are shown
in  Table  1.  The  sample  consists  of  26.7%
never smokers, 48.44% quitters (15.06% quit
within  five  years  and  33.38%  prior  to  five
years), 14.5% current smokers (2.8%, 5.46%
and 16.56% have pack-years <20, 20-39 and
≥40). Also, 24.85%, 5.81% and 13.39% had a
duration of <30 years, 30-39 years and ≥40
years  while  4.11%,  8.21%  and  12.53%  had
smoking intensity of less than 20 cigarettes
per day, 20-39 cigarettes per day and 40 or
more cigarettes per day. 
Table 2a shows that the inclusion of pack-
years among current smokers in our measure
of smoking status (model 3) improved predic-
tive ability significantly compared to the mod-
els which included smoking status as a sim-
ple dichotomous variable (model 1) and cur-
rent/past/never  smoker  variable  (model  2).
The  models  without  control  (Table  2a)  and
with control (Table 2b) for pack-years indicat-
ed excellent calibration. 
The inclusion of time since quitting in our
measure  of  smoking  status  (model  4)  per-
formed well in terms of model discrimination
and overall fit but not so well in terms of cali-
bration (Table 2b). Model 4 improved predic-
tive  ability  significantly  based  on  global  fit
and  reclassification  statistics  compared  to
model 1 and model 2 (Table 2c).  
The models incorporating pack-years and
time since quitting (model 5), and the joint
effect of both intensity and duration of smok-
ing, and time since quitting (model 6), per-
formed well in terms of all model performance
indicators (Table 2d).  These models showed
significantly  improved  prediction  perform-
ance in terms of global fit and reclassification
measures compared to the models with a sim-
ple current/non-smoker measure of smoking
status and current/past/never smoker meas-
ure of smoking status, respectively (Tables 2e
and f). Table 2e further shows that model 5
predicts  significantly  better  than  models  3
and 4. 
The best risk prediction equation
Table 2e further shows that, as expected,
improvement in discrimination through c sta-
tistic for model 5 relative to models 1 through
4 is moderate as the c statistic for the latter
(reference)  models  was  already  fairly  high
(this is a limitation of the c statistic as dis-
cussed in Materials and Methods). Based on
AIC  and  BIC,  model  5  predicts  better  than
models 1 through 4 and model 6 when model
parsimony is taken into consideration (Table
2g). (Since models 5 and 6 are not nested,
they can only be ranked using AIC and BIC).
Thus, model 5 is the preferred model.      
Table  2b  shows  that,  compared  to  never
smokers, the risk of CVD incidence increased
with  past  smoking  status  and  pack-years
among  current  smokers  for  which  the
increase  in  risk  seemed  to  slow  down  for
those with exposure to 40 or more pack-years.
Those who quit within five years prior to the
baseline exam had a risk of developing a CVD
event almost 2 times higher than those who
never smoked, while those who quit prior to
five years had a similar risk to never smokers.
Reclassification of subjects 
In this section, we describe how many sub-
jects  were  reclassified  overall  and  with
respect to ‘high risk’ category of more than
20% when we used our preferred full model
(model 5) as compared to model 1. Based on
Table 3a, for 383 subjects who experienced a
CVD  event,  using  model  5  as  compared  to
model 1, the net gain in reclassification pro-
portion was significantly different from zero
(P=0.0001).  This  statistic  for  subjects  who
did not experience an event was not signifi-
cant. Overall, for all 3,751 subjects, the net
gain  in  reclassification  proportion  was
0.0711, significantly different from zero.        
If we had used model 5 rather than model 1,
19.3%  of  those  who  develop  CVD  would  be
appropriately assessed for their cardiovascu-
lar risk while only 11.4% of those who do not
develop  CVD  would  be  falsely  assessed  for
their  cardiovascular  risk,  the  difference  of
which is highly significant (P<0.0001).
Simpler developing cardiovascular
disease risk prediction equations
using non-laboratory risk factors
The  simple  office  or  non-laboratory  risk
factor-based  CVD  risk  prediction  equation
Table 1. Summary of statistics for risk factors (at exam 4) used in risk models for total
population characteristics.
Summary statistic
Sex, N (%)
Females 1937 (51.64)
Males 1814 (48.36)
Age (years), mean (SD) 51.61 (9.63)
Total-C (mg/dL), mean (SD) 206.30 (39.17)
HDL-C (mg/dL), mean (SD) 49.52 (14.80)
Systolic blood pressure (mmHg), mean (SD) 127.11 (18.89)
Diastolic blood pressure (mmHg), mean (SD) 79.25 (10.01)
Triglycerides (meq/liter), mean (SD) 125.92 (101.34)
Alcohol (ounce), mean (SD) 2.89 (4.39)
Total cholesterol (mg/dL), mean (SD) 206.31 (39.17)
HDL cholesterol (mg/dL), mean (SD) 49.52 (14.80)
Total/HDL cholesterol ratio, mean (SD) 4.54 (1.65)
Body mass index (kg/m
2), mean (SD) 26.86 (4.81)
Never smoking, N (%) 1002 (26.71)
Past smoking, N (%) 1817 (48.44)
Time since quitting ≤5 years, N (%) 565 (15.06)
Time since quitting >5 years, N (%) 1252 (33.38)
Current smoking, N (%) 932 (24.85)
Pack-years <20, N (%) 105 (2.80)
Pack-years 20-39, N (%) 206 (5.49)
Pack-years 40+, N (%) 621 (16.56)
Duration of smoking <30 years, N (%) 212 (5.65)
Duration of smoking 30-39 years, N (%) 218 (5.81)
Duration of smoking 40+ years, N (%) 502 (13.39)
Intensity of smoking <20 cigarettes (per day), N(%)  154 (4.11)
Intensity of smoking 20-39 cigarettes (per day), N(%)    308 (8.21)
Intensity of smoking 40+ cigarettes (per day), N (%) 470 (12.53)
Diabetes, N (%) 163 (4.35)Article
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incorporating the joint effects of pack-years
and  time  since  quitting  and  non-laboratory
risk factors (model 11) performed reasonably
well  (data  not  shown).  Compared  to  this
model, the corresponding full model (model
5) predicts better both in terms of global fit
and  discrimination  (Table  3b).  The  simple
office-based CVD risk prediction model incor-
porating the effects of intensity and duration
of smoking, time since quitting  and non-lab-
oratory risk factors (model 12) also performed
reasonably  well  (data  not  shown).  The
improvement in global fit and discrimination
for the corresponding full model was also sig-
nificant (Table 3c).
The best reduced risk prediction
equation
Table 3d shows that, based on the global fit
statistic and the measures of reclassification,
model 11 predicts the risk of CVD incidence
significantly better than models with non-lab-
oratory risk factors and a yes/no measure of
current  smoking  status  (model  7),
current/past/never smoker measure of smok-
ing status (model 8), pack-years incorporated
into the smoking status variable (model 9)
and time since quitting incorporated into the
smoking status variable (model 10). Again as
Table 2a. Model performance statistics for the model with current/non-smoker measure
of smoking (model 1) and improvement in prediction due to including pack-years in
model 3.
Statistic Value Degrees of freedom P
Hosmer Lemeshow 4.6310 9 0.8652
Modified HL 4.3962 9 0.8835
Likeliood ratio 312.0313 8 <0.0001
C (SE) 0.8041 (0.0109)
95% CI 0.7827-0.8255
Likelihood ratio
Model 3 vs. Model 1 12.9552 3 0.0047
Model 3 vs. Model 2 9.1547 1 0.0025
Difference between  Estimate (SE) 95% CI c2 P
two correlated C
Model 3 vs. Model 1 0.0023 (0.0022) -0.0020, 0.0066 1.0678 0.3014
Model 3 vs. Model 2 0.0018 (0.0018) -0.0017, 0.0053 1.0086 0.3152
Estimate 95% CI Z P 
NRI
Model 3 vs. Model 1 0.0033 0.0012, 0.0054  3.0628 0.0022
Model 3 vs. Model 2 0.0160 -0.0034, 0.0354 1.6160 0.1061
IDI
Model 3 vs. Model 1 0.0332 0.0029, 0.0636 2.1406 0.0323
Model 3 vs. Model 2 0.0021 0.0006, 0.0037 2.7307 0.0063
Table 2b. Risk equations of models 3 and 4.
Model 3 Model 4
incorporating pack-years and  incorporating time since quitting in past 
other risk factors smoking status and other risk factors
Estimate (SE) Hazard Ratio (95% CI) Estimate (SE) Hazard Ratio (95% CI)
Smoking variables
Smoking status (Never smoker)
Past smoker 0.3167**** (0.1306) 1.373 (1.063, 1.773)
Pack-years
<20 0.3320 (0.2734) 1.394 (0.816, 2.382)
20-39 0.9049*(0.2271) 2.472 (1.584, 3.857)
40+ 0.9617*(0.1789)   2.616 (1.842, 3.714)
Time since quitting
≤5 years   0.7744* (0.1823)    2.169 (1.518,3.101)
>5 years 0.0163 (0.1310)  1.016 (0.786, 1.314)
Current smoker 0.7003* (0.1373) 2.014 (1.539,2.637)
Total 3751 3751
Event 383 383
Censored 3368 3368
% censored 89.79 89.79
c2 P c2 P
Test
Likelihood ratio 455.5912 <0.0001 456.578 <0.0001
Hosmer lemeshow 9.21449 0.4177 19.0085     0.0251
Modified HL 8.56713 0.4782 17.9658      0.0355
C-statistic
Estimate (SE) 0.8047 (0.0110)    0.8082 (0.0109)
95% CI (0.7832, 0.8263) (0.7869, 0.8296)
The coefficients for the smoking variables have been adjusted for the effects of age, sex, SBP, DBP, total cholesterol/HDL ratio, triglycerides, diabetes and alcohol. The reference category for a categorical variable is
in the parentheses. *, **, *** and **** indicate P<0.0001, 0.001, 0.01 and 0.05, respectively. The statistical tests presented at the bottom of the table are for the full model versus the null model.Article
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expected,  improvement  in  c  statistic  for
model 11 relative to models 7 through 10 is
moderate as the c statistic for the latter (ref-
erence) models was already fairly high. AIC
and BIC indicate that when model parsimony
is taken into consideration, model 11 fits bet-
ter than model 12 and models 7 through 10
(Table 3e). (Since models 11 and 12 are not
nested, they have only been ranked using AIC
and BIC.) Thus, model 11 is the best model.
Reclassification of subjects 
Table 3f shows that when our best reduced
model (model 11) was used compared to the
reduced  model  with  a  current  smoker/non-
smoker measure (model 7), for all 3,751 sub-
jects the net gain in reclassification propor-
tion  was  significantly  different  from  zero
(P<0.0001). For comparing model 5 against
model 11, reclassifications for subjects with
and without events are summarized in Table
Table 2d. Risk equations of models 5 and 6.
Model 5 Model 6
incorporating both pack-years and  incorporating both intensity and  
time since quitting and other risk factors duration of smoking and time since quitting 
and other risk factors
Estimate (SE) Hazard Ratio (95% CI) Estimate (SE) Hazard Ratio (95% CI)
Smoking variables
Smoking status (Never smoker)
Past smoker
Pack-years
<20 0.1487 (0.3437)  1.160 (0.592, 2.276)
20-39 0.8254**(0.2181) 2.283 (1.489, 3.501)
40+ 0.8038*(0.1646)    2.234 (1.618, 3.085)
Time since quitting
≤5 years   0.7813*(0.1822)  2.184 (1.528, 3.122) 0.7808*(0.1824) 2.183 (1.527, 3.122)
>5 years 0.0147 (0.1312) 1.015 (0.785, 1.312) 0.0179 (0.1311) 1.018 (0.787, 1.316)
Intensity<20 and 
duration <30 0.7112 (0.5091) 2.037 (0.751, 5.524)
30-39 0.7757****(0.3449) 2.172 (1.105, 4.271)
40+ 0.3254 (0.3472)     1.385 (0.701, 2.735)
Intensity 20-39 and
duration <30 0.4986 (0.4652)       1.646(0.661, 4.098)
30-39 0.7926***(0.2740)     2.209 (1.291, 3.780)
40+ 0.5652****(0.2298) 1.760 (1.122, 2.761)
Intensity 40+  and
duration <30 1.3344***(0.4654)    3.798 (1.525, 9.457) 
30-39 1.2824** (0.3477)  3.605 (1.824, 7.127)
40+ 1.0216****(0.4200)    2.778 (1.220, 6.327)
Total          3751 3751
Event           383 383
Censored   3368 3368
% Censored 89.8    89.8
c2 P c2 P
Likelihood ratio 463.7085 <0.0001 466.1424        <0.0001
Hosmer Lemeshow 16.0902     0.0650       13.9224     0.1251     
Modified HL 15.2299      0.0848 13.1900      0.1541       
C-statistic
Estimate (SE) 0.8084 (0.0109)     0.8092 (0.0109)
95% CI (0.7869, 0.8298) (0.7878, 0.8305)
The coefficients for the smoking variables have been adjusted for the effects of age, sex, SBP, DBP, total cholesterol/HDL ratio, triglycerides, diabetes and alcohol. The reference category for a categorical variable is
in the parentheses. *, **, *** and ****  indicate P<0.0001, 0.001, 0.01 and 0.05, respectively. The statistical tests presented at the bottom of the table are for the full model versus the null model.
Table 2c. Improvement in prediction due to including time since quitting among past
smokers in model 4.
Likelihood ratio Value Degrees of freedom P
Vs. model 1 15.9421 2 0.0003
Vs. model 2 11.3852 1 0.0007
Difference between  Estimate (SE) 95% CI c2 P
two correlated C
Vs. model 1 0.0041 (0.0027)    -0.0011, 0.0094 2.3715   0.1236
Vs. model 2 0.0036 (0.0026) -0.0014, 0.0087 2.0005 0.1572
Estimate  95% CI ZP
NRI
Vs. model 1 0.0394 0.0122, 0.0666     2.8332     0.0046
Vs. model 2 0.0222 -0.0092, 0.0537     1.3832  0.1666
IDI
Vs. model 1 0.0020 -0.0004, 0.0046   1.5924 0.1112
Vs. model 2 0.0009 -0.0017, 0.0036 0.6823 0.4950Article
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3g.  For  all  3,751  subjects,  the  net  gain  in
reclassification  proportion  was  significantly
different from zero (P=0.034). For 3,368 sub-
jects who did not experience a CVD event, the
net  gain  in  reclassification  proportion  was
significantly different from zero (P<0.0001)
while for 383 subjects who experienced a CVD
event this was not (P=0.0943). 
If we had used model 5 rather than model
11, 18.02% of those who develop CVD would
be appropriately assessed for their cardiovas-
cular risk while only 10.2% of those who do
not develop CVD would be falsely assessed for
their  cardiovascular  risk,  the  difference  of
which is highly significant (P<0.0001).
Strengths and limitations
The equations derived from this study have
several  advantages  over  previous  versions.
The inclusion of detailed smoking measures
rather  than  a  crude  dichotomous  yes/no
smoking  measure  in  the  risk  equations  is
novel. We have also used a more recent popu-
lation cohort to develop the risk equations.
The  influence  of  high  density  lipoprotein
(HDL) cholesterol, which has been measured
in the Framingham Heart Study since 1968, is
also  reflected  in  our  equations.  Also,  the
influence of alcohol intake which has been
measured  in  the  Framingham  Heart  Study
since  its  initiation  is  reflected  in  the  risk
equations. Alcohol intake was not included in
any of the previously developed risk equations
for  predicting  CVD  events  based  on  the
Framingham data.    
One limitation of the present study is that
the  Framingham  sample  is  predominantly
Caucasian, so the generalizability of the CVD
risk function in other ethnic groups is uncer-
tain. Other Framingham risk functions have
shown themselves to recalibrate well in other
samples.
10,11,28,29
Discussion
This  study  demonstrated  the  benefits  of
adding  detailed  smoking  measures  to  CVD
risk prediction equations. Incorporating pack-
years  among  current  smokers  significantly
improved  prediction  and  so  did  time  since
Table 2e. Comparison of model 5 with models 1 through 4.
Likelihood ratio Value Degrees of freedom P
Vs. model 1 21.0725 4 0.0003
Vs. model 2 16.5156 3 0.0008
Vs. model 3  11.5018  1 0.0006
Vs. model 4          6.1304   2 0.0466
Difference between  Estimate (SE) 95% CI c2 P
two correlated C
Vs. model 1 0.0042 (0.0030)        -0.0016, 0.0101      2.0284   0.1544
Vs model 2 0.0037 (0.0029) -0.0019, 0.0094 1.6927  0.1932
Vs. model 3 0.0036 (0.0026)  -0.0014, 0.0086 1.9864 0.1587 
Vs. model 4 0.0001 (0.0013)      -0.0024, 0.0026 0.0075  0.9310                                                           
Estimate  95% CI ZP
NRI
Vs. model 1 0.0711 0.0347, 0.1075 3.8260 0.0001
Vs. model 2 0.0438 0.0131, 0.0745    2.7904     0.0052
Vs. model 3 0.0213 -0.0093, 0.0520 1.3630 0.1728
Vs. model 4 0.0043  -0.0099, 0.0187    0.5983 0.5496    
IDI
Vs. model 1 0.0037 0.0007, 0.0066     2.4830   0.0130
Vs. model 2 0.0025 -0.0004, 0.0056 1.6543 0.0980
Vs. model 3 0.0010 -0.0017, 0.0037  0.7267 0.4673
Vs. model 4 0.0016  0.0002, 0.0030  2.2511  0.0243  
Table 3a. Reclassification table between the best model with a detailed smoking measure
(model 5) and the model with a current/non-smoker smoking measure (model 1) as the
reference model.
Model 1 Model 5
Frequency (row per cent)  <6 %  6-20 %  >20%  Total
Participants who experience a CVD event
<6 % 148 27 0 175
6-20% 8 123 10 141
>20% 03 64 67
Total 156 153 74 383
Net gain in reclassification proportion (P) 0.0678 (0.0001)
Participants who do not  experience a CVD event
<6 % 1746 56 0 1802
6-20% 105 1072 44 1221
>20% 06 339 345
Total 1851 1134 383 3368
Net gain in reclassification proportion (P) 0.0032 (0.4488)
NRI (P) 0.0711 (0.0001)
Table 2f. Improvement in prediction due to including both intensity and duration of
smoking among current smokers in model 6.
Likelihood ratio Value Degrees of freedom P
Vs. model 1 23.5064 10 0.0090
Vs. model 2 18.9495 9 0.0256
Difference between  Estimate (SE) 95% CI c2 P
two correlated C
Vs. model 1 0.0050 (0.0030)   -0.0009, 0.0110      2.7338     0.0982
Vs. model 2 0.0045 (0.0029)    -0.0012, 0.0103       2.3760   0.1232
Estimate  95% CI ZP
NRI
Vs. model 1                      0.0440 0.0120, 0.0761     2.6845  0.0072
Vs. model 2 0.0268 0.0073, 0.0611     -1.5365 0.1244
IDI
Vs. model 1 0.0031 -0.00008, 0.0062 1.9101   0.0561
Vs. model 2 0.0019   -0.0013, 0.0052   1.1773 0.2390
Table 2g. Information indices for models 1
through 6.
Model BIC AIC
1 5908.260  5836.753
2 5880.559 5834.197
3 5873.677 5833.183
4 5875.005    5824.811
5 5868.240 5823.681  
6 5872.286   5833.247 Article
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quitting  among  past  smokers.  When  both
these  variables  were  incorporated  in  the
smoking variable compared to using a simple
current smoker/non-smoker variable, 7.1% of
subjects changed their risk categories which
was statistically significant.  
We observed that the risk of CVD incidence
first  increased  with  pack-years  but  then
slightly  declined  at  high  exposure  to  pack-
years.  Although  in  some  other  cohorts  the
beneficial  effect  of  smoking  cessation  has
been found to be as early as 1-3 years,
8,9 we
observed that any major reduction in the risk
of CVD incidence did not occur until after five
years  since  quitting.  Compared  to  never
smokers,  the  risk  of  CVD  incidence  was
almost twice as high for those who had quit
within five years prior to baseline while this
risk reduced to the level of never smokers for
those who had quit more than five years ago.
We observed that the risk of CVD incidence
first increased with both intensity and dura-
tion  of  smoking  but  then  declined  at  high
duration and not at high intensities. 
We also showed that if we had incorporated
time since quitting and pack-years in smok-
ing  status  instead  of  using  a  simple
current/non-smoker measure, a significantly
higher proportion of those developing a CVD
event would have moved up to the ‘high risk’
category compared to those not having a CVD
event  who  moved  up  to  this  category.  The
result was similar when we excluded labora-
tory  based  risk  factors  from  the  models.  In
each case, the former participants would be
appropriately assessed while the latter  would
be falsely assessed if we incorporated time
since quitting and pack-years in smoking sta-
tus. Those appropriately assessed can benefit
from additional screening for CVD risk and
would require more aggressive intervention
for smoking cessation,
41 and this would assist
in  preventing  more  deaths.  However,  this
benefit would be at the cost of falsely identify-
ing people who do not develop CVD as high
risk. These people may unnecessarily receive
additional screening, and it may even cause
undue stress and burden to various smoking
cessation programs. The performance of the
model which incorporates time since quitting
and pack-years, when considered in this per-
spective,  relies  on  the  relative  importance
one places on these benefits and costs. From
a  CVD  prevention  perspective,  the  benefits
associated  with  smoking  cessation  for  pre-
vention  of  CVD  clearly  outweigh  the  costs
associated with CVD screening and smoking
cessation programs.
Our risk prediction equations are unlikely
to be seriously affected by confounding bias
as we have adjusted for all major confounders
of smoking, including age, sex, alcohol con-
sumption and the blood pressure components.
We  conducted  further  analyses  of  the  off-
spring cohort to explore the possibility of any
effect of distortion medical treatments may
have on risk of CVD incidence, and found that
the regression coefficients of the risk equa-
tions were fairly robust after adjustment for
cardioactive  medications  (data  not  shown).
We also explored the possibility of the effect
of reverse causation, as there may be some
reduction in the apparent risk of CVD inci-
dence  among  current  smokers  (and  hence
among different categories of pack-years and
their components) because of a tendency for
people to give up smoking after they begin to
be influenced by some life threatening condi-
Table 3b. Lack of fit statistics due to excluding laboratory risk factors from the equation
with pack-years, time since quitting and other risk factors (models 11 vs. 5).
Test Value Degrees of freedom P
Likelihood ratio 56.4307 3 <0.0001
Difference between  Estimate (SE) 95% CI c2 P
two correlated C
0.0173 (0.0039)     0.0096,     0.0250      19.3872   <0.0001
Estimate  95% CI ZP
NRI 0.0662 0.0220, 0.1104      2.9248     0.0034
IDI 0.0149 0.0079, 0.0218 4.2177 <0.0001
Table 3c. Lack of fit statistics due to excluding laboratory risk factors from the equation
with intensity, duration of smoking, time since quitting and other risk factors (models 12
vs. 6).
Test Value Degrees of freedom P
Likelihood ratio 56.6429 3 <0.0001
Difference between  Estimate (SE) 95% CI c2 P
two correlated C
0.0173 (0.0040)     0.0095,     0.0250      18.8621   <0.0001
Estimate  95% CI ZP
NRI 0.0625 0.0171,  0.1078          2.9248     0.0034
IDI 0.0151 0.0082,  0.0220    4.3264 <0.0001
*Indicates conditional likelihood ratio test for model 6 versus model 5.
Table 3d. Comparison of model 11 with models 7 through 10. 
Likelihood ratio Value Degrees of freedom P
Vs. model 7 25.0982 4 <0.0001
Vs. model 8 20.4029 3 0.0001
Vs. model 9  15.6708 1 <0.0001
Vs. model 10    6.7224       2 0.0346
Difference between  Estimate (SE) 95% CI c2 P
two correlated C
Vs. model 7 0.0055 (0.0033) -0.0010, 0.0121       2.7246   0.0988
Vs. model 8 0.0048 (0.0032) -0.0015 , 0.0111 2.2025 0.1378        
Vs. model 9 0.0043 (0.0029) -0.0014, 0.0101 2.1770  0.1401    
Vs. model 10              0.0004 (0.0013) -0.0021, 0.0029 0.1125  0.7373  
Estimate  95% CI ZP
NRI
Vs. model 7 0.0767 0.0398, 0.11361 4.0786 <0.0001
Vs. model 8 0.0435 0.0112, 0.0758 2.6323 0.0084   
Vs. model 9 0.0023 0.0293, 0.0340     0.1431  0.8862  
Vs. model 10 0.0140 -0.00002, 0.0281  1.9534            0.0507 
IDI
Vs. model 7 0.0048 0.0016, 0.0080   3.0020 0.0026
Vs. model 8 0.0035   0.0003, 0.0067   2.1472  0.0317 
Vs. model 9 0.0020 -0.0009, 0.0049 1.3443   0.1788
Vs. model 10 0.0015 0.0001, 0.0028  2.1944   0.0282             Article
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tion, such that their risk of CVD incidence
may  or  may  not  be  caused  by  smoking.  To
reduce this bias, we conducted a sub-analysis
where we excluded from our baseline cohort
those with a history of cancer and other non-
CVD conditions (data not shown). This exclu-
sion did not substantially affect the results.
Sub-analyses conducted whereby we excluded
from our baseline cohort those smokers who
gave  up  smoking  after  examination  4  and
those  quitters  who  took  up  smoking  after
examination 4, and later those current smok-
ers from our baseline cohort whose smoking
intensity or duration changed dramatically in
subsequent  examinations,  did  not  substan-
tially alter our results.   
Incorporating pack-years, time since quit-
ting and individual components of pack-years
in the smoking status variable, and adjusting
for other risk factors in the risk equations,
produced very good discrimination and cali-
bration. However, since the c statistic for the
CVD risk equations with the full set of risk
factors  ranged  from  0.8041  to  0.8100,  this
suggested  that  additional  risk  factors  (e.g.
age at quitting, types of cigarettes, environ-
mental smoking, abdominal obesity,  family
history  of  CVD,  etc.)  may  further  improve
model discrimination. 
In conclusion, we have demonstrated that
CVD risk equations including a simple cur-
rent smoker/non-smoker variable underesti-
mate the overall effect of cigarette smoking,
as  risk  prediction  improves  significantly
when pack-years and time since quitting are
incorporated.  We  advocate  the  use  of
improved risk prediction equations incorpo-
rating  more  detailed  smoking  measures  in
order to ensure current prevention strategies
are optimally effective and cost-effective, and
that ex-smokers are not consistently under-
treated.      
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